Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Oncotarget, 7, 15, S. 20033-20040
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2016
- Event
-
Veröffentlichung
- (who)
-
Impact Journals, LLC
- (when)
-
2016
- Creator
-
Lapa, Constantin Frederik Victor
Hänscheid, Heribert
Wild, Vanessa
Pelzer, Theo
Schirbel, Andreas
Wolf, Herta
Droll, Sabine
Herrmann, Ken
Buck, Andreas K.
Lückerath, Katharina
- DOI
-
10.18632/oncotarget.7706
- URN
-
urn:nbn:de:bvb:384-opus4-634505
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:49 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lapa, Constantin Frederik Victor
- Hänscheid, Heribert
- Wild, Vanessa
- Pelzer, Theo
- Schirbel, Andreas
- Wolf, Herta
- Droll, Sabine
- Herrmann, Ken
- Buck, Andreas K.
- Lückerath, Katharina
- Universität Augsburg
- Impact Journals, LLC
Time of origin
- 2016
Other Objects (12)
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Imaging of myocardial inflammation with somatostatin receptor based PET/CT: a comparison to cardiac MRI
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Ein 18F markiertes PET-Radiopharmakon (LMI1195) zur Bildgebung des Norepinephrin-Stoffwechsels im Rattenherz
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Imaging of myocardial inflammation with somatostatin receptor based PET/CT: a comparison to cardiac MRI
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Ein 18F markiertes PET-Radiopharmakon (LMI1195) zur Bildgebung des Norepinephrin-Stoffwechsels im Rattenherz
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Imaging of myocardial inflammation with somatostatin receptor based PET/CT: a comparison to cardiac MRI
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy